Infant
Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market
Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus
Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants
Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee
Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial
Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results
HilleVax Discontinues Norovirus Vaccine for Infants After Mid-Stage Trial Failure
HilleVax, norovirus vaccine, infants, mid-stage trial, failure, discontinuation